Plasma Galectin-3 and urine proteomics predict FEV(1) improvement in omalizumab-treated patients with severe allergic asthma: Results from the PROXIMA sub-study()

BACKGROUND: Patients with severe allergic asthma (SAA) when treated with omalizumab may exhibit different extent of response. Identifying biomarkers that can predict the extent of treatment effectiveness in patients can be useful in personalizing omalizumab treatment. METHODS: Patients from the long...

Descripción completa

Detalles Bibliográficos
Autores principales: Riccio, Anna Maria, Mauri, Pierluigi, De Ferrari, Laura, Rossi, Rossana, Di Silvestre, Dario, Bartezaghi, Marta, Saccheri, Fabiana, Canonica, Giorgio Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992845/
https://www.ncbi.nlm.nih.gov/pubmed/32015785
http://dx.doi.org/10.1016/j.waojou.2019.100095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992845/
https://www.ncbi.nlm.nih.gov/pubmed/32015785
http://dx.doi.org/10.1016/j.waojou.2019.100095

Ejemplares similares